Status:

NOT_YET_RECRUITING

Transmaculine One-on-One and Group Empowerment for Targeted HIV Reduction

Lead Sponsor:

Fenway Community Health

Collaborating Sponsors:

National Institute of Mental Health (NIMH)

Conditions:

HIV Infections

Adherence, Medication

Eligibility:

FEMALE

18+ years

Phase:

NA

Brief Summary

Transgender masculine and gender diverse people who have sex with men (TMSM) have an increased risk of HIV and face unique barriers engaging in prevention services. Digitally delivered support interve...

Detailed Description

This study will comprise a digitally delivered, open-label randomized 2x2 factorial trial (1:1:1:1 randomization) of peer-delivered HIV prevention strategies. The 2x2 factorial design has two actors: ...

Eligibility Criteria

Inclusion

  • Age 18 or over
  • Assigned female sex at birth
  • Identifies as a man, trans man, or another transmasculine identity
  • Has had sex with a partner assigned male sex at birth with a flesh penis in the last 3 months
  • Has access to a smartphone or computer with internet access
  • Is HIV-uninfected
  • Resides in one of the Ending the Epidemic targeted geographic hotspots in the United States
  • Willing and able to provide informed consent in English
  • Meets CDC guidelines for PrEP indications in the last 3 months (adapted for TMSM) including:
  • Condomless receptive vaginal/frontal or anal sex with a partner assigned male at birth with a flesh penis
  • Sharing needles or syringes for illicit drug use and/or hormones
  • Self-reported anogenital sexually transmitted infection diagnosis

Exclusion

  • Less than age 18
  • Not assigned female sex at birth
  • Does not identify as a man, trans man, or another transmasculine identity
  • Does not have access to a smartphone or computer
  • Is living with HIV (HIV positive)
  • Does not reside in one of the Ending the Epidemic geographic hotspots in the United States
  • Will not or cannot provide written informed consent in English
  • Does not meet the trans-adapted CDC guidelines for PrEP indications

Key Trial Info

Start Date :

January 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2027

Estimated Enrollment :

375 Patients enrolled

Trial Details

Trial ID

NCT06182280

Start Date

January 1 2024

End Date

June 1 2027

Last Update

December 26 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Fenway Community Health

Boston, Massachusetts, United States, 02215

Transmaculine One-on-One and Group Empowerment for Targeted HIV Reduction | DecenTrialz